Five Takeaways From Commissioner Gottlieb's Talk At The National Press Club
Executive Summary
Among the topics US FDA Commissioner Gottlieb touched on were the agency's efforts to reduce clinical development burdens, improve information-sharing and comply with President Trump's two-for-one regulations order.
You may also be interested in...
Neurostimulator Is First Device Marketed To Reduce Opioid Withdrawal Symptoms
FDA used its de novo pathway to clear Innovative Health Solution's NSS-2 Bridge – the first device for use in helping to reduce the symptoms of opioid withdrawal – as a class II device.
Q&A Exclusive: FDA Commissioner Talks About His Tenure, Recruiting And LDTs
US FDA Commissioner Scott Gottlieb sat down with Medtech Insight and Pink Sheet reporters for an exclusive chat about his ongoing regulatory work and plans for the future.
For Some Companies, Puerto Rico Financial Impact Uncertain
Lantheus Holdings, Becton Dickinson are among manufacturers to say in recent financial reports that the hurricane has ongoing impacts for the companies.